Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study.

J. Sewell; V. Cambiano; A. Speakman; F.C. Lampe; A. Phillips; D. Stuart; R. Gilson; D. Asboe; N. Nwokolo; A. Clarke; A.J. Rodger

doi:10.1016/j.drugpo.2019.03.021

Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study.

J. Sewell, V. Cambiano, A. Speakman, F.C. Lampe, A. Phillips, D. Stuart, R. Gilson, D. Asboe, N. Nwokolo, A. Clarke, A.J. Rodger

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Recent evidence has suggested that chemsex (the use of mephedrone, crystal methamphetamine and γ -hydroxybutyrate/ γ -butryolactone (GHB/GBL) to enable, enhance and prolong sexual interactions) has increased among men having sex with men (MSM) attending sexual health clinics in large UK cities. To date there has been no data from the UK or Europe that describes changes in chemsex over time within a cohort of MSM. METHODS: The prospective cohort study, Attitudes to and Understanding Risk of Acquisition of HIV over Time (AURAH2), collected online questionnaire data from HIV negative or undiagnosed MSM (at enrolment) from 2015 to 2018, recruited from sexual health clinics. We aim to investigate changes in chemsex, three individual drugs associated with chemsex, frequency of chemsex sessions and measures of sexual behaviour, among the cohort of MSM over the study's 3 year follow-up period. RESULTS: In total 622 MSM completed at least one online questionnaire for the AURAH2 study, of which 400 (64.3%) were still engaged with the study within the last six months of follow-up. Prevalence of chemsex significantly declined during the follow-up from 31.8% (198/622) at the first online questionnaire, to 11.1% (8/72; p

Original language	English
Pages (from-to)	54-61
Number of pages	8
Journal	Int J Drug Policy
Volume	68
DOIs	https://doi.org/10.1016/j.drugpo.2019.03.021
Publication status	Published - 15 Apr 2019

Keywords

Chemsex
Cohort
Condomless sex
HIV prevention
Longitudinal
Men who have sex with men
Sexual behaviour
Sexual health

Access to Document

10.1016/j.drugpo.2019.03.021

1-s2.0-S0955395919300854-mainFinal published version, 1.71 MBLicence: CC BY-NC-ND

https://www.ncbi.nlm.nih.gov/pubmed/30999243

Fingerprint Dive into the research topics of 'Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study.'. Together they form a unique fingerprint.

Cite this

@article{2028e5097bc7449b87a9b9ef9f57e312,

title = "Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study.",

abstract = "BACKGROUND: Recent evidence has suggested that chemsex (the use of mephedrone, crystal methamphetamine and γ -hydroxybutyrate/ γ -butryolactone (GHB/GBL) to enable, enhance and prolong sexual interactions) has increased among men having sex with men (MSM) attending sexual health clinics in large UK cities. To date there has been no data from the UK or Europe that describes changes in chemsex over time within a cohort of MSM. METHODS: The prospective cohort study, Attitudes to and Understanding Risk of Acquisition of HIV over Time (AURAH2), collected online questionnaire data from HIV negative or undiagnosed MSM (at enrolment) from 2015 to 2018, recruited from sexual health clinics. We aim to investigate changes in chemsex, three individual drugs associated with chemsex, frequency of chemsex sessions and measures of sexual behaviour, among the cohort of MSM over the study's 3 year follow-up period. RESULTS: In total 622 MSM completed at least one online questionnaire for the AURAH2 study, of which 400 (64.3%) were still engaged with the study within the last six months of follow-up. Prevalence of chemsex significantly declined during the follow-up from 31.8% (198/622) at the first online questionnaire, to 11.1% (8/72; p ",

keywords = "Chemsex, Cohort, Condomless sex, HIV prevention, Longitudinal, Men who have sex with men, Sexual behaviour, Sexual health",

author = "J. Sewell and V. Cambiano and A. Speakman and F.C. Lampe and A. Phillips and D. Stuart and R. Gilson and D. Asboe and N. Nwokolo and A. Clarke and A.J. Rodger",

year = "2019",

month = apr,

day = "15",

doi = "10.1016/j.drugpo.2019.03.021",

language = "English",

volume = "68",

pages = "54--61",

journal = "Int J Drug Policy",

issn = "1873-4758",

}

Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study. / Sewell, J.; Cambiano, V.; Speakman, A.; Lampe, F.C.; Phillips, A.; Stuart, D.; Gilson, R.; Asboe, D.; Nwokolo, N.; Clarke, A.; Rodger, A.J.

In: Int J Drug Policy, Vol. 68, 15.04.2019, p. 54-61.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study.

AU - Sewell, J.

AU - Cambiano, V.

AU - Speakman, A.

AU - Lampe, F.C.

AU - Phillips, A.

AU - Stuart, D.

AU - Gilson, R.

AU - Asboe, D.

AU - Nwokolo, N.

AU - Clarke, A.

AU - Rodger, A.J.

PY - 2019/4/15

Y1 - 2019/4/15

N2 - BACKGROUND: Recent evidence has suggested that chemsex (the use of mephedrone, crystal methamphetamine and γ -hydroxybutyrate/ γ -butryolactone (GHB/GBL) to enable, enhance and prolong sexual interactions) has increased among men having sex with men (MSM) attending sexual health clinics in large UK cities. To date there has been no data from the UK or Europe that describes changes in chemsex over time within a cohort of MSM. METHODS: The prospective cohort study, Attitudes to and Understanding Risk of Acquisition of HIV over Time (AURAH2), collected online questionnaire data from HIV negative or undiagnosed MSM (at enrolment) from 2015 to 2018, recruited from sexual health clinics. We aim to investigate changes in chemsex, three individual drugs associated with chemsex, frequency of chemsex sessions and measures of sexual behaviour, among the cohort of MSM over the study's 3 year follow-up period. RESULTS: In total 622 MSM completed at least one online questionnaire for the AURAH2 study, of which 400 (64.3%) were still engaged with the study within the last six months of follow-up. Prevalence of chemsex significantly declined during the follow-up from 31.8% (198/622) at the first online questionnaire, to 11.1% (8/72; p

AB - BACKGROUND: Recent evidence has suggested that chemsex (the use of mephedrone, crystal methamphetamine and γ -hydroxybutyrate/ γ -butryolactone (GHB/GBL) to enable, enhance and prolong sexual interactions) has increased among men having sex with men (MSM) attending sexual health clinics in large UK cities. To date there has been no data from the UK or Europe that describes changes in chemsex over time within a cohort of MSM. METHODS: The prospective cohort study, Attitudes to and Understanding Risk of Acquisition of HIV over Time (AURAH2), collected online questionnaire data from HIV negative or undiagnosed MSM (at enrolment) from 2015 to 2018, recruited from sexual health clinics. We aim to investigate changes in chemsex, three individual drugs associated with chemsex, frequency of chemsex sessions and measures of sexual behaviour, among the cohort of MSM over the study's 3 year follow-up period. RESULTS: In total 622 MSM completed at least one online questionnaire for the AURAH2 study, of which 400 (64.3%) were still engaged with the study within the last six months of follow-up. Prevalence of chemsex significantly declined during the follow-up from 31.8% (198/622) at the first online questionnaire, to 11.1% (8/72; p

KW - Chemsex

KW - Cohort

KW - Condomless sex

KW - HIV prevention

KW - Longitudinal

KW - Men who have sex with men

KW - Sexual behaviour

KW - Sexual health

U2 - 10.1016/j.drugpo.2019.03.021

DO - 10.1016/j.drugpo.2019.03.021

M3 - Article

VL - 68

SP - 54

EP - 61

JO - Int J Drug Policy

JF - Int J Drug Policy

SN - 1873-4758

ER -